Gene clues may predict blood cancer outcomes
NCT ID NCT02619565
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study enrolled 349 people with myelodysplastic syndromes (MDS) to see how certain gene mutations affect survival. Researchers collected blood samples at diagnosis and tracked patients over time. The goal was to understand which mutations are linked to better or worse outcomes, which could help guide future treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better predict disease progression and tailor treatments for people with myelodysplastic syndromes.
- What could go wrong
- This is an observational study, not a treatment trial. It only looks at genetic patterns and does not test any new therapy, so it cannot directly improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIXED MYELODYSPLASTIC/MYELOPROLIFERATIVE DISORDERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Assistance publique-Hôpitaux de Paris, Hôpital Cochin
Paris, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- Can engineered immune cells outsmart Hard-to-Treat blood cancers?
- Can a new drug offer hope for blood cancers when chemo fails?